Moreover, there is no consensus regarding the use of TMB as a selection criteria for PD-1/PD-L1 antibody therapy because it would require whole exome sequencing or large scale sequencing of several target genes in the tumor samples of NSCLC patients [6, 8]. This evidence concerns the gene CD274 and neoplasm.